Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Nishikawa

Showing results (111-120 of 197) with videos related to

Pageof 20
Sort By:
Journal of Gastroenterology|May 31, 2024
Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinomaTakumi Habu, Shogo Kumagai, Hideaki Bando, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2018
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibodyDanbee Ha, Atsushi Tanaka, Tatsuya Kibayashi, et al.
International Journal of Hematology|June 13, 2023
Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantationCarolyne Barakat, Yuichiro Inagaki, Shohei Mizuno, et al.
JCI Insight|March 23, 2021
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancerKoji Inamori, Yosuke Togashi, Shota Fukuoka, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2019
PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancerTakahiro Kamada, Yosuke Togashi, Christopher Tay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)Akihito Kawazoe, Yasutoshi Kuboki, Eiji Shinozaki, et al.
Scientific Reports|April 12, 2023
Anti-tumor effects of anti-programmed cell death-1 antibody treatment are attenuated in streptozotocin-induced diabetic miceMasaaki Ito, Shintaro Iwama, Daisuke Sugiyama, et al.
Journal for Immunotherapy of Cancer|April 3, 2025
Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumorsKoichi Jinushi, Takuro Saito, Koji Kurose, et al.
Journal of Cancer Research and Clinical Oncology|February 14, 2018
Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lungTakuya Ueda, Keiju Aokage, Hiroyoshi Nishikawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2015
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer PatientsKoji Kurose, Yoshihiro Ohue, Hisashi Wada, et al.
Pageof 20

Showing results (111-120 of 197) with videos related to

Sort By:
Pageof 20
Journal of Gastroenterology|May 31, 2024
Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinomaTakumi Habu, Shogo Kumagai, Hideaki Bando, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2018
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibodyDanbee Ha, Atsushi Tanaka, Tatsuya Kibayashi, et al.
International Journal of Hematology|June 13, 2023
Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantationCarolyne Barakat, Yuichiro Inagaki, Shohei Mizuno, et al.
JCI Insight|March 23, 2021
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancerKoji Inamori, Yosuke Togashi, Shota Fukuoka, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2019
PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancerTakahiro Kamada, Yosuke Togashi, Christopher Tay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)Akihito Kawazoe, Yasutoshi Kuboki, Eiji Shinozaki, et al.
Scientific Reports|April 12, 2023
Anti-tumor effects of anti-programmed cell death-1 antibody treatment are attenuated in streptozotocin-induced diabetic miceMasaaki Ito, Shintaro Iwama, Daisuke Sugiyama, et al.
Journal for Immunotherapy of Cancer|April 3, 2025
Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumorsKoichi Jinushi, Takuro Saito, Koji Kurose, et al.
Journal of Cancer Research and Clinical Oncology|February 14, 2018
Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lungTakuya Ueda, Keiju Aokage, Hiroyoshi Nishikawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2015
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer PatientsKoji Kurose, Yoshihiro Ohue, Hisashi Wada, et al.
Pageof 20